ASA Plavix Feasibility Study With WATCHMAN Left Atrial Appendage Closure Technology

ASA Plavix Feasibility Study With WATCHMAN Left Atrial Appendage Closure Technology

The purpose of the study is to characterize the performance of the WATCHMAN LAA Closure Device in atrial fibrillation patients for which long term warfarin therapy is contraindicated.

Inclusion Criteria:

• 18 years of age or older
• paroxysma, persistent, or permanent non-vlavular atrial fibrillation
• contraindicated to warfarin
• eligible for clopidogrel, ticlopdine, heparin, or aspirin
• CHADS score 1 or greater

Exclusion Criteria:

• NYHA Class IV
• LAA obliteration
• Heart transplant
• LVEF less than 30%
• greater than 50% carotid stenosis